Keros Therapeutics Inc.

10.21
0.17 (1.69%)
At close: Apr 03, 2025, 2:09 PM

Keros Therapeutics Statistics

Share Statistics

Keros Therapeutics has 40.56M shares outstanding. The number of shares has increased by 12.41% in one year.

Shares Outstanding 40.56M
Shares Change (YoY) 12.41%
Shares Change (QoQ) 0.13%
Owned by Institutions (%) 99.99%
Shares Floating 32.88M
Failed to Deliver (FTD) Shares 29
FTD / Avg. Volume < 0.01%

Short Selling Information

The latest short interest is 4.02M, so 9.92% of the outstanding shares have been sold short.

Short Interest 4.02M
Short % of Shares Out 9.92%
Short % of Float 12.23%
Short Ratio (days to cover) 2.14

Valuation Ratios

The PE ratio is -3.16 and the forward PE ratio is -3.11. Keros Therapeutics's PEG ratio is 0.82.

PE Ratio -3.16
Forward PE -3.11
PS Ratio 166.94
Forward PS 3.2
PB Ratio 1.04
P/FCF Ratio -3.64
PEG Ratio 0.82
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Keros Therapeutics.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 21.45, with a Debt / Equity ratio of 0.03.

Current Ratio 21.45
Quick Ratio 21.45
Debt / Equity 0.03
Debt / EBITDA -0.1
Debt / FCF -0.12
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $21.01K
Profits Per Employee $-1.11M
Employee Count 169
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax 300K
Effective Tax Rate -0.16%

Stock Price Statistics

The stock price has increased by -84.31% in the last 52 weeks. The beta is 1.4, so Keros Therapeutics's price volatility has been higher than the market average.

Beta 1.4
52-Week Price Change -84.31%
50-Day Moving Average 11.1
200-Day Moving Average 38.31
Relative Strength Index (RSI) 35.1
Average Volume (20 Days) 1.33M

Income Statement

In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.

Revenue 3.55M
Gross Profit 3.55M
Operating Income -210.83M
Net Income -187.35M
EBITDA -185.82M
EBIT -187.05M
Earnings Per Share (EPS) -5
Full Income Statement

Balance Sheet

The company has 559.93M in cash and 18.86M in debt, giving a net cash position of 541.07M.

Cash & Cash Equivalents 559.93M
Total Debt 18.86M
Net Cash 541.07M
Retained Earnings -568.78M
Total Assets 615.89M
Working Capital 561.44M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -160.87M and capital expenditures -1.93M, giving a free cash flow of -162.8M.

Operating Cash Flow -160.87M
Capital Expenditures -1.93M
Free Cash Flow -162.8M
FCF Per Share -4.35
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -5938.96% and -5277.55%.

Gross Margin 100%
Operating Margin -5938.96%
Pretax Margin -5269.1%
Profit Margin -5277.55%
EBITDA Margin -5234.48%
EBIT Margin -5938.96%
FCF Margin -4585.92%

Dividends & Yields

KROS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for KROS is $26, which is 159% higher than the current price. The consensus rating is "Hold".

Price Target $26
Price Target Difference 159%
Analyst Consensus Hold
Analyst Count 13
Stock Forecasts

Scores

Altman Z-Score 4.05
Piotroski F-Score 4